RTI Biologics, Inc. (RTIX)

[surf1944]

RTI Biologics, Inc. (RTIX) process human musculoskeletal and other tissue. It also processes bone, cartilage, tendon, ligament, fascia lata, pericardium, sclera and dermal tissue, and bovine animal tissue in producing allograft and xenograft implants utilizing biocleanse and tutoplast sterilization processes, for distribution to hospitals and surgeons. The current market price is $3.65 with a one-year analyst price target of $5.13. This represents a 40.55% upside potential.

Over the past three years, the company has reported three positive (>2%), zero negative, and one in-line (within 2%) surprises. The average surprise for this time period has been 26.0%. Most recently on 01/31/12, the company reported quarterly earnings of 0.04 per share, a positive surprise of 25.0% above the consensus 0.03. For fiscal year 2012, analysts estimate that RTIX will earn $0.16 and for 2013, analysts estimate that RTIX's earnings per share will grow by 37% to $0.22. Over the past five years EPS growth rate has been 35.21% and are expected to be 28.40% over the next five years. RTIX has a long-term debt / equity ratio of 0 and a PEG of 0.87 further making this a great value stock that is poised for growth.

http://seekingalpha.com/article/441311-4-extremely-undervalued-stocks-to-add-to-your-portfolio?source=yahoo